Preliminary note on the antipsychotic efficacy of bromperidol.
Bromperidol was administered to 20 acute and chronic psychotic inpatients during six to eight weeks at a mean daily dose of 18 to 10 mg. The neuroleptic was given orally or intramuscularly once a day (in the morning in order to evaluate its therapeutic and side effects). In 13 patients, bromperidol was substituted for haloperidol; in 7 cases, it was given immediately after the washout period. Descriptive psychopathology was complemented with quantitative psychopathology (ad hoc 29-item scale, AMDP Psychopathology Scale, Bf/Bf' Mood Scales). According to a preliminary analysis of data, both descriptive and psychometric, bromperidol seems to be a potent antipsychotic drug without disturbing adrenolytic side-effects or sedation, with classical extrapyramidal effects of the hypertonia type.
D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*
D006220:Haloperidol